Simply Wall St reaffirms CHF 110.00 fair value for Bachem stock

Published on 10/06/2026 at 14:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bachem stock costs EUR 88.08 on October 6, 2026 after EUR 85.25, plus 3.32 percent. Sales rose 4.30 percent to CHF 326.40 million in first half of 2026.

Fotorealistische Peptid-Produktionsanlage mit Alpenpanorama im Hintergrund — Bachem Holding AG (CH0012530207) betreibt moderne Peptid-Produktionsanlagen mit Bioreaktoren vor Schweizer Alpenpanorama, Illustration mit AI erstellt.

Bachem stock (ISIN CH1176493729) was trading at EUR 88.08 at Lang & Schwarz on October 6, 2026 at 2:32 p.m. CEST, up 3.32 percent from the prior close of EUR 85.25. On October 6, 2026, Simply Wall St reaffirmed a CHF 110.00 fair value for Bachem. The valuation anchor puts capacity execution and customer demand at the center of the investment debate.

CHF 110 fair value holds

Simply Wall St said its fair value remained CHF 110.00 in the October 6, 2026 update. The same analysis raised its revenue growth assumption from 32.40 percent to 34.38 percent, while increasing the discount rate from 4.57 percent to 4.80 percent.

That combination matters because the higher growth assumption supports the valuation, while the higher discount rate works in the opposite direction. The unchanged fair value therefore depends more heavily on Bachem converting planned capacity into revenue.

First-half sales grew 4.30 percent

In the first-half 2026 earnings call carried by Yahoo Finance, Bachem reported sales of CHF 326.40 million, up 4.30 percent from the first half of 2025. Local-currency growth was 7.30 percent, showing that the Swiss franc reduced the reported increase.

EBITDA, or earnings before interest, taxes, depreciation and amortization, reached CHF 82.80 million and the EBITDA margin was 25.40 percent in the first half of 2026. Management maintained its 2026 outlook for sales growth of 35.00 percent to 40.00 percent in local currencies and an EBITDA margin in the low 30s.

Analyst targets remain divided

Investing.com listed an average 12-month target of CHF 84.30 from 10 analysts. The table showed six Buy ratings, three Hold ratings and one Sell rating, with JPMorgan maintaining a CHF 90.00 target on September 10, 2026, after CHF 85.00.

Barclays maintained a Hold rating and lifted its target from CHF 70.00 to CHF 80.00 on September 8, 2026. The spread between the CHF 80.00 Barclays target and the CHF 90.00 JPMorgan target highlights the different assumptions surrounding Bachem's expansion pace.

Trading reference for Bachem stock

Bachem stock was trading at EUR 88.08 at Lang & Schwarz on October 6, 2026 at 2:32 p.m. CEST, versus the Lang & Schwarz prior close of EUR 85.25 on October 5, 2026. The next financial results are listed for December 1, 2026 by Investing.com.

The further course of trading is shown by the continuously updated real-time quote of Bachem stock.